Intravenous Vitamin C in the Treatment of Viral Infection, Especially in the Treatment of Shingles (168)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00921934|
Recruitment Status : Completed
First Posted : June 17, 2009
Results First Posted : October 26, 2012
Last Update Posted : December 21, 2017
Chronic viral infections induce oxidative stress that can cause a number of concomitant diseases, e.g. cardio-vascular diseases or metabolic disorders. Therefore, a sufficient treatment of oxidative stress may be of benefit for the patient to prevent further diseases.
Shingles (herpes zoster infection) have been successfully treated with antioxidative substances like high-dose vitamin C for ages. Not only the acute symptoms can be diminished by high-dose vitamin C. Even long-term sequelae, like painful post-herpetic neuropathy, may be mitigated or even fully avoided.
|Condition or disease|
|Virus Diseases Herpes Zoster|
|Study Type :||Observational|
|Actual Enrollment :||68 participants|
|Official Title:||PASCORBIN 7.5g in the Treatment of Viral Infection, Especially Varicella Zoster Infection: An Observational Cohort Study|
|Study Start Date :||April 2009|
|Actual Primary Completion Date :||December 2010|
|Actual Study Completion Date :||December 2010|
Adult patients suffering from acute viral infection, especially herpes zoster, presenting themselves in Primary Care Centers or hospitals all over Germany, and who are treated with standard therapy and add-on vitamin C.
- Change of Pain Measured by VAS [ Time Frame: visit 1 - 3 ]VAS (minimum = 0 = no pain, maximum = 10 = extrem pain, change of pain measured by VAS
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00921934
|Praxis Dr. Schencking, Rheinstr. 77a|
|Ransbach-Baumbach, Rheinland-Pfalz, Germany, 56235|
|Principal Investigator:||Martin Schencking, MD||Rheinstr. 77a, D-56235 Ransbach-Baumbach|
|Study Director:||Bianka Krick||Pascoe Pharmazeutische Praeparate GmbH|